Abstract：Objective To observe the efficacy and safety of recombinant human brain natriuretic peptide (rhBNP) when used in elderly patients.Methods A total of 319 elder patients with heart failure were chosen from our hospital between January 2012 and June 2017.They were randomly divided into the control group (n=138) and rhBNP treatment group (n=181).Patients in both groups were observed and compared in terms of type B natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), ventricular shortening index (FS), the 6-minute walk test (6 MWT), changes of liver function, renal function and blood pressure, and the difference in the rate of re-hospitalization.Results After 5 days, the level of NT-proBNP in the rhBNP treatment group was significantly lower than that in the control group (P<0.05), but LVEF, FS and 6MWT increased (P<0.05). Three months after treatment, the level of NT-proBNP in the rhBNP treatment group was significantly lower than that in the control group (P<0.05), but LVEF, FS and 6MWT improved significantly (P<0.05). After 3 months of treatment, the rate of re-hospitalization in the rhBNP treatment group was significantly lower than that in the control group (P<0.05).Conclusions Recombinant human brain natriuretic peptide (rhBNP) is safe and effective in the treatment of acute exacerbation of chronic heart failure in elderly patients, which can reduce the re-hospitalization rate of heart failure that occurs within 3 months.
Houston B A, Kalathiya R J, Kim D A, et al. Volume overload in heart failure: evidence-based review of strategies for treatment and prevention[J]. Mayo Clin Proc, 2015, 7(16): 196-199.
[2]
Lehnart S E, Terrenoire C, Reiken S, et al. Stabilization of cardiac ryanodine receptor prevents intracellular calcium leak and arrhythmias[J]. Proc Natl Acad Sci USA, 2006, 103(20): 7906-7910.
[3]
Szilagyi S, Pollesello P, Levijoki J, et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations, and phosphodiesterase enzymes of the guinea pig[J]. Eur J Pharmacol, 2004, 486(1): 67-74.
[4]
Gheorghiade M, Teerlink J R, Mebazaa A. Phamacology of new agents for acute heart failure syndromes[J]. Am J Cardiol, 2005, 96(6A): 68-73.
[5]
Lup. A M,Gastelurrutia P,De Antonio M,et al.Quality of life monitoring in ambulatory heart failure patients: temporal changes and prognostic value[J]. Eur J Heart Fail, 2013,15(1): 103-109.
[6]
Jourdain P,Jondenu G,Funck F,et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: BNP Multicenter Study[J]. J Am College Cardiol, 2007, 49( 16) : 1733-1739.
Han B, Li H, Ma Q. Clinical therapeutic strategy of recombinant human brain natriuretic peptide and dopamine in cardiorenal syndrome type 4 patients combined with hypotension [J]. Pak J Pharm Sci, 2017, 30(4): 1449-1453.
[10]
Xu H, Wang B, Meng Q,et al. Effectiveness and safety of recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction in elderly in combination with cardiac failure[J]. Pak J Med Sci, 2017, 33(3): 540-544.
[11]
Saenger A K, Rodriguez-Fraga O, Ler R, et al. Specificity of B-type natriuretic peptide assays: cross-reactivity with different BNP, NT-proBNP, and proBNP peptides[J]. Clin Chem, 2017, 63(1):351-358.
[12]
He X M, Chen L, Luo J B, et al. Effects of rhBNP after PCI on non-invasive hemodynamic in acute myocardial infarction patients with left heart failure[J]. Asian Pac J Trop Med, 2016, 9(8):791-795.
[13]
Torres-Courchoud I, Chen H H. B-type natriuretic peptide and acute heart failure: fluid homeostasis, biomarker and therapeutics[J]. Rev Clin Esp, 2016, 216(7): 393-398.
[14]
Lanfear D E, Li J, Abbas R, et al. Genetic factors influencing B-type natriuretic peptide-mediated production of cyclic guanosine monophosphate and blood pressure effects in heart failure patients[J]. Cardiovasc Transl Res, 2015, 8(9):545-553.
[15]
Zhang Y, Gao F, Zhang X Y, et al. Value of human brain natriuretic peptide in treatment of acute anterior myocardial infarction evaluated via three-dimensional speckle tracking imaging [J]. Genet Mol Res, 2015, 14(2): 5699-5709.
[16]
Holditch S J, Schreiber C A, Nini R, et al. B-type natriuretic peptide deletion leads to progressive hypertension, associated organ damage, and reduced survival: novel model for human hypertension[J]. Hypertension, 2015, 66(1):199-210.
[17]
Ding Y, Peng Y, Deng L, et al. The effects of fusion structure on the expression and bioactivity of human brain natriuretic peptide (BNP) albumin fusion proteins[J]. Curr Pharm Biotechnol, 2014, 15(9):856-863.
[18]
Wang S, Qu X, Qu Y, et al. The effect of B-type brain natriuretic peptide on patients with acute decompensated heart failure coexisting with lung cancer: a randomized controlled clinical trial [J]. Pharmazie, 2014, 69(3): 212-216.
2019, Vol. 30 
